Association between syndecan-4 and subclinical atherosclerosis in ankylosing spondylitis

Basit Öğe Kaydı
dc.contributor.authorSertdemir, Ahmet L.
dc.contributor.authorSahin, Ahmet T.
dc.contributor.authorDuran, Mustafa
dc.contributor.authorCelik, Mustafa
dc.contributor.authorTatar, Sefa
dc.contributor.authorOktay, Irem
dc.contributor.authorAlsancak, Yakup
dc.date.accessioned2024-02-23T14:21:14Z
dc.date.available2024-02-23T14:21:14Z
dc.date.issued2024
dc.departmentNEÜen_US
dc.description.abstractBackground: Despite advances in the diagnosis and treatment of ankylosing spondylitis (AS), the risk of cardiovascular complications in AS patients is still higher than in the general population. Macrophages are at the intersection of the basic pathogenetic processes of AS and atherosclerosis. Although syndecan-4 (SDC4) mediates a variety of biological processes, the role of SDC4 in macrophage-mediated atherogenesis in AS patients remains unclear. Herein, we aimed to investigate the role of SDC4 in subclinical atherosclerosis in AS patients.Methods: Subjects were selected from eligible AS patients and control subjects without a prior history of AS who were referred to the rheumatology outpatient clinics. All participants' past medical records and clinical, and demographic characteristics were scanned. In addition, carotid intima-media thickness (CIMT) measurement and disease activity index measurement were applied to all patients.Results: According to our data, serum SDC4 level was significantly higher among AS patients compared with the control group (6.7 [1.5-35.0] ng/mL vs 5.1 [0.1-12.5] ng/mL, P < .001). The calculated CIMT was also significantly higher in AS patients than in the control group (0.6 [0.3-0.9] mm vs 0.4 (0.2-0.7), P < .001]. Additionally, serum C-reactive protein level and SDC4 level were independent predictors of AS and strongly associated with CIMT. Linear regression analysis showed that serum SDC4 level was the best predictor of CIMT (P = .004).Conclusion: Our data indicate that serum SDC4 levels provide comprehensive information about the clinical activity of the disease and subclinical atherosclerosis in AS patients.en_US
dc.identifier.doi10.1097/MD.0000000000037019
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue3en_US
dc.identifier.pmid38241528en_US
dc.identifier.scopus2-s2.0-85182859962en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000037019
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13509
dc.identifier.volume103en_US
dc.identifier.wosWOS:001145855300055en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofMedicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnkylosing Spondylitisen_US
dc.subjectSubclinical Atherosclerosisen_US
dc.subjectSyndecan-4en_US
dc.titleAssociation between syndecan-4 and subclinical atherosclerosis in ankylosing spondylitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu